magnolol has been researched along with hematoxylin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, M; Guo, W; Huang, L; Liu, Y; Sun, H; Wang, N; Wu, Y; Xu, L; Yang, Y | 1 |
1 other study(ies) available for magnolol and hematoxylin
| Article | Year |
|---|---|
Magnolol limits NFκB-dependent inflammation by targeting PPARγ relieving retinal ischemia/reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Eosine Yellowish-(YS); Glaucoma; Hematoxylin; Inflammation; Ischemia; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; PPAR gamma; Reperfusion Injury; Retina | 2022 |